Algorae Pharmaceuticals (ASX: 1AI) has entered into an exclusive licencing agreement with Indian pharmaceutical manufacturer Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets. Algorae has commenced regulatory planning for registration of the products with the Therapeutic Goods Administration on the pathway to commercialisation. Vertically-Integrated GroupSakar is a vertically-integrated pharmaceutical group specialising in the production of active pharmaceutical ingredients and finished dosage forms, with a strong focus on oncology. Sakar exports to over 60 countries including regulated markets in Europe and across Asia, Africa, and Latin America. Algorae chair David Hainsworth said the licencing agreement was the first step towards establishing a presence in Australia and New Zealand that would expand the company’s commercial footprint and position it for long-term growth.